Decoy Therapeutics Inc. (DCOY)

Every figure this model derived for DCOY, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 577,000 PaymentsToAcquireProductiveAssets 2025-12-31
cash 8,289,108 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 8,573,308 AssetsCurrent 2026-06-30
current liabilities 4,680,254 LiabilitiesCurrent 2026-06-30
equity 4,320,906 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2026-06-30
ocf -8,324,525 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 227,629 Revenues 2026-06-30
sbc 581,590 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up DCOY on one particular measure came for.

RatioValue
current ratio1.83
current ratio reported1.83
deferred revenue growth-100.0
dilution pct20.95
growth cv21.2
sbc pct revenue255.5

What to be careful about

What this model itself distrusts about DCOY's figures. Written by the derivation as it ran, not added afterwards.